 SAN FRANCISCO, March 09, 2021 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurixs chief executive officer, will participate and present at the following conferences in March: 